|Free Dividend Report|
|Stock Splits Calendar|
|MBVX Stock Split History|
|Preferred Stock Newsletter|
|Top Option Ideas|
|Stock Message Boards|
MBVX (MBVX) has 2 splits in our MBVX split history database. The first split for MBVX took place on August 17, 2016. This was a 135 for 1000 reverse split, meaning for each 1000 shares of MBVX owned pre-split, the shareholder now owned 135 shares. For example, a 1000 share position pre-split, became a 135 share position following the split. MBVX's second split took place on February 16, 2018. This was a 1 for 3 reverse split, meaning for each 3 shares of MBVX owned pre-split, the shareholder now owned 1 share. For example, a 135 share position pre-split, became a 45 share position following the split.
When a company such as MBVX conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the MBVX split history from start to finish, an original position size of 1000 shares would have turned into 45 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into MBVX shares, starting with a $10,000 purchase of MBVX, presented on a split-history-adjusted basis factoring in the complete MBVX split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-45.56%|
|MabVax Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co. discovers and develops proprietary human monoclonal antibody products for the diagnosis and treatment of a variety of cancers. Therapeutic vaccines under development were discovered at Memorial Sloan Kettering Cancer Center and are licensed to Co.'s subsidiary, MabVax Therapeutics, Inc. Co.'s development program is centered around its HuMab-5B1 antibody, which is discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial. The antigen the antibody targets is expressed on pancreatic cancers, small cell lung cancer, stomach, colon and other cancers. According to our MBVX split history records, MBVX has had 2 splits.|
|MBVX Split History Table|
|08/17/2016||135 for 1000|
|02/16/2018||1 for 3|
|Healthcare Stock Splits|
|MBVX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: MBVX shares outstanding history